Skip to main content
. 2017 Apr 10;8(34):56443–56459. doi: 10.18632/oncotarget.16992

Table 3. List of biopsies included in this study with patient clinicopathologic parameters and immunohistochemical staining scores for ERβ and MMP-2.

Case No. Gender Age at time of surgery Tumor Stage UICC Tumor Stage TNM Lymphnode metastasis ratio IHC score of ERβ IHC score of MMP2
Primary Tumor Lymphnode Metastasis Primary Tumor Lymphnode Metastasis
01 Female 48 IIIA pT2aN2 11/13 ++ ++ + +
02 Male 64 IIIA pT2aN2 11/26 + +++ + -
03 Male 66 IIIA pT2bN2 5/21 ++ +++ - -
04 Male 21 IIIA pT2bN2 6/26 ++ ++ - -
05 Male 63 IIIA pT2bN2 4/16 ++ ++ ++ +
06 Male 57 IIIA pT2aN2 7/16 + +++ + -
07 Male 46 IIIA pT2aN2 5/27 +++ +++ - ++
08 Female 58 IIIB pT3N3 4/14 + +++ +++ +
09 Male 52 IIIA pT2aN2 5/18 ++ ++ - -
10 Male 38 IIIB pT4N2 4/16 ++ ++ - -
11 Male 60 IIB pT2bN1 2/40 + +++ + -
12 Male 58 IIIA pT3N2 11/18 +++ +++ - ++
13 Male 53 IIIB pT2bN3 14/20 ++ +++ - ++
14 Female 57 IIIB pT1bN3 9/12 +++ +++ + +
15 Male 42 IIIA pT2aN2 14/32 +++ +++ + +
16 Male 72 IIIA pT2aN2 7/11 ++ +++ + +
17 Male 64 IIB pT2aN1 1/10 ++ ++ + ++
18 Male 61 IIIA pT2bN2 2/10 +++ +++ ++ ++
19 Male 65 IIIB pT4N2 1/32 +++ +++ - +
20 Male 66 IIIA pT2bN2 4/8 +++ ++ - ++
21 Male 67 IIB pT2aN1 2/14 ++ +++ - +
22 Male 53 IIIA pT2aN2 11/23 +++ +++ - +
23 Male 59 IIIA pT2aN2 16/31 ++ +++ + -
24 Male 45 IIIB pT2aN3 8/11 + +++ - +
25 Male 60 IIIA pT3N2 9/35 +++ ++ - -
26 Male 59 IIIA pT2aN2 7/20 ++ +++ + -
27 Male 47 IIIA pT2aN2 12/18 ++ +++ - +
28 Male 69 IIIA pT2bN2 2/37 + +++ + ++
29 Male 57 IIIA pT3N1 1/11 + +++ - -
30 Male 60 IIIA pT2aN2 5/11 ++ +++ - -
ERβ primary vs. LN t value p value Median score Median score
4.402 <0.001 11.10 14.57